Aleksandar Videnovic, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, introduces the NIH-funded NeuroNEXT network, a robust and accessible infrastructure to facilitate rapid development and implementation of clinical trial protocols in neurological disorders. The Network for Excellence in Neuroscience Clinical Trials brings together a Clinical Coordinating Center (CCC), a Data Coordinating Center (DCC) and 20 clinical sites to support the development and execution of Phase II studies and biomarker discovery studies. Dr Videnovic notes that anyone can apply to conduct a study within the network, including academic investigators, advocacy groups, small businesses, and the pharmaceutical industry, where they will receive substantial support for protocol optimization and grant submission to NINDS. Notably, NeuroNEXT is now supporting the development of trials of gene-based and gene-targeted therapies for ultra-rare neurological diseases. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
